A new era: melanoma genetics and therapeutics (Q37815139)

23 August 2017

1 reference

title

A new era: melanoma genetics and therapeutics (English)

1 reference

23 August 2017

Justin M Ko

1

1 reference

PubMed ID

21125678

23 August 2017

David E Fisher

series ordinal

2

1 reference

23 August 2017

28 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

223

1 reference

23 August 2017

2

1 reference

23 August 2017

241-250

1 reference

23 August 2017

Cancer statistics, 2009

1 reference

Cutaneous melanoma: available therapy for metastatic disease

21 January 2018

1 reference

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

21 January 2018

1 reference

Human melanocyte senescence and melanoma susceptibility genes

21 January 2018

1 reference

21 January 2018

1 reference

Genetic alterations in signaling pathways in melanoma

21 January 2018

1 reference

Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

21 January 2018

1 reference

Melanoma biology and new targeted therapy

21 January 2018

1 reference

Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer

21 January 2018

1 reference

Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells

21 January 2018

1 reference

No Evidence for BRAF as a melanoma/nevus susceptibility gene

21 January 2018

1 reference

Malignant melanoma: genetics and therapeutics in the genomic era.

21 January 2018

1 reference

Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

21 January 2018

1 reference

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

High BRAF mutation frequency does not characterize all melanocytic tumor types.

21 January 2018

1 reference

BRAF mutations are common somatic events in melanocytic nevi.

21 January 2018

1 reference

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

21 January 2018

1 reference

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

Oncogenic Braf induces melanocyte senescence and melanoma in mice

21 January 2018

1 reference

Use of human tissue to assess the oncogenic activity of melanoma-associated mutations

21 January 2018

1 reference

Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies

21 January 2018

1 reference

The specificity of p53 mutation spectra in sunlight induced human cancers.

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

MC1R variants increase risk of melanomas harboring BRAF mutations.

21 January 2018

1 reference

The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

21 January 2018

1 reference

Chemotherapy and targeted therapy combinations in advanced melanoma

21 January 2018

1 reference

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy

21 January 2018

1 reference

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

21 January 2018

1 reference

The role of B-RAF in melanoma.

21 January 2018

1 reference

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling

21 January 2018

1 reference

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

21 January 2018

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

21 January 2018

1 reference

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase

21 January 2018

1 reference

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

21 January 2018

1 reference

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas

21 January 2018

1 reference

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors

21 January 2018

1 reference

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

21 January 2018

1 reference

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

21 January 2018

1 reference

21 January 2018

Main roads to melanoma

1 reference

Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines

21 January 2018

1 reference

Cellular survival: a play in three Akts

21 January 2018

1 reference

PTEN signaling pathways in melanoma

21 January 2018

1 reference

The protein kinase B/Akt signalling pathway in human malignancy

21 January 2018

1 reference

PI 3-kinase, Akt and cell survival

21 January 2018

1 reference

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

Regulation of cell death protease caspase-9 by phosphorylation

21 January 2018

1 reference

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling

21 January 2018

1 reference

Deregulated Akt3 activity promotes development of malignant melanoma

21 January 2018

1 reference

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

21 January 2018

1 reference

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

21 January 2018

1 reference

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

21 January 2018

1 reference

Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.

21 January 2018

1 reference

A novel transforming gene in a human malignant melanoma cell line

21 January 2018

1 reference

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

21 January 2018

1 reference

Recurrent patterns of dual RB and p53 pathway inactivation in melanoma

21 January 2018

1 reference

BRAF alterations are associated with complex mutational profiles in malignant melanoma.

21 January 2018

1 reference

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression

21 January 2018

1 reference

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

The role of Bcl-2 family members in the progression of cutaneous melanoma

21 January 2018

1 reference

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

The implications of angiogenesis for the biology and therapy of cancer metastasis

21 January 2018

1 reference

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

21 January 2018

1 reference

The vascular phenotype of melanoma metastasis

21 January 2018

1 reference

Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression

21 January 2018

1 reference

Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB

21 January 2018

1 reference

Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.

21 January 2018

1 reference

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

21 January 2018

1 reference

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Immunotherapy for melanoma: current status and perspectives

21 January 2018

1 reference

Recent advances and hurdles in melanoma immunotherapy.

21 January 2018

1 reference

Immunotherapy: Vaccine trials in melanoma -- time for reflection

21 January 2018

1 reference

Immunotherapy for advanced melanoma.

21 January 2018

1 reference

Identification of cells initiating human melanomas

21 January 2018

1 reference

Efficient tumour formation by single human melanoma cells

21 January 2018

1 reference

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

21 January 2018

1 reference

Neonatal sunburn and melanoma in mice

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PATH.2804

1 reference

23 August 2017

1 reference

PubMed ID

21125678